Chandrashekar Reddy Ambati

Chandrashekar Reddy Ambati

Auto-generated profile, based on publicly available information

Chandrashekar Reddy Ambati

Baylor College of Medicine, Houston, TX

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
GFGrant M. Fischer
Grant M. Fischer
AJAli Jalali
Ali Jalali
DKDavid A. Kircher
David A. Kircher
WLWon-Chul Lee
Won-Chul Lee
JMJennifer L. McQuade
Jennifer L. McQuade
MDMichael A Davies
Michael A Davies
There is a critical need to improve our understanding of the pathogenesis of melanoma brain metastases (MBM). Thus, we performed RNA sequencing on 88 resected MBMs and 42 patient-matched extracranial metastases; tumors with sufficient tissue also underwent whole-exome sequencing, T-cell receptor sequencing, and IHC. MBMs demonstrated heterogeneity of immune infiltrates that correlated with prior radiation and post-craniotomy survival. Comparison with patient-matched extracranial metastases identified significant immunosuppression and enrichment of oxidative phosphorylation (OXPHOS) in MBMs. Gene-expression analysis of intracranial and subcutaneous xenografts, and a spontaneous MBM model, confirmed increased OXPHOS gene expression in MBMs, which was also detected by direct metabolite profiling and [U-13C]-glucose tracing in vivo. IACS-010759, an OXPHOS inhibitor currently in early-phase clinical trials, improved survival of mice bearing MAPK inhibitor–resistant intracranial melanoma xenografts and inhibited MBM formation in the spontaneous MBM model. The results provide new insights into the pathogenesis and therapeutic resistance of MBMs. Significance: Improving our understanding of the pathogenesis of MBMs will facilitate the rational development and prioritization of new therapeutic strategies. This study reports the most comprehensive molecular profiling of patient-matched MBMs and extracranial metastases to date. The data provide new insights into MBM biology and therapeutic resistance. See related commentary by Egelston and Margolin, p. 581. This article is highlighted in the In This Issue feature, p. 565

3 June 2019 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
QHQingsong Hu
Qingsong Hu
Youqiong YeYouqiong Ye
Youqiong Ye
LCLi-Chuan Chan
Li-Chuan Chan
YLYajuan Li
Yajuan Li
KLKe Liang
Ke Liang
Liuqing YangLiuqing Yang
Liuqing Yang

28 January 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YLYajuan Li
Yajuan Li
QHQingsong Hu
Qingsong Hu
CLChunlai Li
Chunlai Li
KLKe Liang
Ke Liang
YXYu Xiang
Yu Xiang
Chunru LinChunru Lin
Chunru Lin
Epithelial-mesenchymal transition (EMT) contributes significantly to interstitial matrix deposition in diabetic kidney disease (DKD). However, detection of EMT in kidney tissue is impracticable, and anti-EMT therapies have long been hindered. We reported that phosphatase and tensin homolog (PTEN) promoted transforming growth factor beta 1 (TGF-β), sonic hedgehog (SHH), connective tissue growth factor (CTGF), interleukin 6 (IL-6), and hyperglycemia-induced EMT when PTEN was modified by a MEX3C-catalyzed K27-linked polyubiquitination at lysine 80 (referred to as PTENK27-polyUb). Genetic inhibition of PTENK27-polyUb alleviated Col4a3 knockout–, folic acid–, and streptozotocin-induced (STZ-induced) kidney injury. Serum and urine PTENK27-polyUb concentrations were negatively correlated with glomerular filtration rate (GFR) for diabetic patients. Mechanistically, PTENK27-polyUb facilitated dephosphorylation and protein stabilization of TWIST, SNAI1, and YAP in renal epithelial cells, leading to enhanced EMT. We identified that a small molecule, triptolide, inhibited MEX3C-catalyzed PTENK27-polyUb and EMT of renal epithelial cells. Treatment with triptolide reduced TWIST, SNAI1, and YAP concurrently and improved kidney health in Col4a3 knockout–, folic acid–injured disease models and STZ-induced, BTBR ob/ob diabetic nephropathy models. Hence, we demonstrated the important role of PTENK27-polyUb in DKD and a promising therapeutic strategy that inhibited the progression of DKD.

14 June 2019 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
VVVenkatrao Vantaku
Venkatrao Vantaku
JDJianrong Dong
Jianrong Dong
CAChandrashekar R. Ambati
Chandrashekar R. Ambati
DPDimuthu Perera
Dimuthu Perera
SDSri Ramya Donepudi
Sri Ramya Donepudi
Nagireddy PutluriNagireddy Putluri
Nagireddy Putluri
Purpose: The perturbation of metabolic pathways in high-grade bladder cancer has not been investigated. We aimed to identify a metabolic signature in high-grade bladder cancer by integrating unbiased metabolomics, lipidomics, and transcriptomics to predict patient survival and to discover novel therapeutic targets. Experimental Design: We performed high-resolution liquid chromatography mass spectrometry (LC-MS) and bioinformatic analysis to determine the global metabolome and lipidome in high-grade bladder cancer. We further investigated the effects of impaired metabolic pathways using in vitro and in vivo models. Results: We identified 519 differential metabolites and 19 lipids that were differentially expressed between low-grade and high-grade bladder cancer using the NIST MS metabolomics compendium and lipidblast MS/MS libraries, respectively. Pathway analysis revealed a unique set of biochemical pathways that are highly deregulated in high-grade bladder cancer. Integromics analysis identified a molecular gene signature associated with poor patient survival in bladder cancer. Low expression of CPT1B in high-grade tumors was associated with low FAO and low acyl carnitine levels in high-grade bladder cancer, which were confirmed using tissue microarrays. Ectopic expression of the CPT1B in high-grade bladder cancer cells led to reduced EMT in in vitro, and reduced cell proliferation, EMT, and metastasis in vivo. Conclusions: Our study demonstrates a novel approach for the integration of metabolomics, lipidomics, and transcriptomics data, and identifies a common gene signature associated with poor survival in patients with bladder cancer. Our data also suggest that impairment of FAO due to downregulation of CPT1B plays an important role in the progression toward high-grade bladder cancer and provide potential targets for therapeutic intervention.

6 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ANAswath Narayanan
Aswath Narayanan
PKPrakash Khanchandani
Prakash Khanchandani
RBRoshan Borkar
Roshan Borkar
CAChandrashekar Reddy Ambati
Chandrashekar Reddy Ambati
ARArun Roy
Arun Roy
VSVenketesh Sivaramakrishnan
Venketesh Sivaramakrishnan
Avascular necrosis of the femur head (AVNFH) is a debilitating disease caused due to the use of alcohol, steroids, following trauma or unclear (idiopathic) etiology, affecting mostly the middle aged population. Clinically AVNFH is associated with impaired blood supply to the femoral head resulting in bone necrosis and collapse. Although Homocysteine (HC) has been implicated in AVNFH, levels of homocysteine and its associated pathway metabolites have not been characterized. We demonstrate elevated levels of homocysteine and concomitantly reduced levels of vitamins B6and B12, in plasma of AVNFH patients. AVNFH patients also had elevated blood levels of sodium and creatinine, and reduced levels of random glucose and haemoglobin. Biophysical and ultrastructural analysis of AVNFH bone revealed increased remodelling and reduced bone mineral density portrayed by increased carbonate to phosphate ratio and decreased Phosphate to amide ratio together with disrupted trabeculae, loss of osteocytes, presence of calcified marrow, and elevated expression of osteocalcin in the osteoblasts localized in necrotic regions. Taken together, our studies for the first time characterize the metabolomic, pathophysiological and morphometric changes associated with AVNFH providing insights for development of new markers and therapeutic strategies for this debilitating disorder.

2 January 2019 in Cancer
Verified
Journal Article
Closed access
PDF file
VVVenkatrao Vantaku
Venkatrao Vantaku
SDSri Ramya Donepudi
Sri Ramya Donepudi
DPDanthasinghe Waduge Badrajee Piyarathna
Danthasinghe Waduge Badrajee Piyarathna
CAChandra Sekhar Amara
Chandra Sekhar Amara
CAChandrashekar R. Ambati
Chandrashekar R. Ambati
Nagireddy PutluriNagireddy Putluri
Nagireddy Putluri